X-Chem and AstraZeneca: Using technology to identify lead molecules faster

Since 2012, we’ve been working with US-based X-Chem Inc. to improve the rate and quality of small molecule lead discovery and expand the realm of ‘druggable’ targets. Our successful pilot programme focused on 20 targets. A year later, we expanded the collaboration to multiple therapy areas.